# A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Source: https://onco.cc/trials/nct05288166/  
OnCo record `nct05288166` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abemaciclib and Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) is a phase 3 interventional study registered as NCT05288166 by Eli Lilly and Company, with 925 participants enrolled, started 2022-04-14 and due to reach its primary completion in 2024-02-15. Interventions recorded: Abemaciclib, Abiraterone, Prednisone or Prednisolone and Placebo for Abemaciclib. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05288166
- Phase: 3
- Setting: CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 925

## Sources

- ClinicalTrials.gov NCT05288166: https://clinicaltrials.gov/study/NCT05288166

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05288166.json